Research programme: clade C type HIV vaccines - GeoVax Labs

Drug Profile

Research programme: clade C type HIV vaccines - GeoVax Labs

Alternative Names: C-DNA/MVA; C-MVA

Latest Information Update: 11 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GeoVax Labs
  • Class AIDS vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 29 Jun 2016 GeoVax receives Notice of Award from National Institutes of Health for SBIR grant in Clade C type HIV vaccine development in HIV infections
  • 16 Mar 2016 Preclinical development is ongoing in USA
  • 01 Jul 2015 GeoVax receives Notice of Award from National Institutes of Health for SBIR grant in Clade C type HIV vaccine development in HIV infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top